Pipeline

We are developing an oral formulation of treprostinil (treprostinil diethanolamine). We are currently enrolling two clinical trials to evaluate the safety and efficacy of oral treprostinil in patients with PAH, FREEDOM-C2 and FREEDOM-M. The FREEDOM- C2 trial is a study of patients currently on approved background therapy using a PDE5 inhibitor, such as Revatio® or an ERA, such as Tracleer® or a combination of both. The FREEDOM-M trial is a study of patients who are not on any background therapy.
Lung LLC has licensed the rights from Toray Industries, Inc., a Japanese company, to develop and market Beraprost Sodium Modified Release tablets (BPS-MR) for the treatment of Pulmonary Arterial Hypertension.
BPS-MR has been demonstrated in various pharmacological studies to exhibit potent antiplatelet effects (inhibition of platelet aggregation and adhesion) and vasodilatory effects.
ch14.18 is a chimeric antibody currently being studied in the investigational setting for the treatment of neuroblastoma, a rare pediatric cancer.
We are currently enrolling patients in a Phase II study to investigate the effectiveness of oral treprostinil in reducing the frequency and severity of ulcers located on the fingers and toes of scleroderma patients.
The monoclonal antibody 8H9 is a mouse IgG1 antibody with specificity for the B7H3 antigen. The 8H9 antibody is highly reactive with a range of human solid tumors, including human brain cancers.
Lung LLC entered into a Development Agreement with ImmuneWorks to develop IW001, a purified bovine Type V Collagen oral solution for the treatment of IPF and PGD. We expect to commence human clinical testing of IW001 in 2010.
This is a broad-spectrum antiviral drug platform using glycobiology molecules called iminosugars, which have shown activity against multiple viruses such as West Nile, influenza, dengue and Hepatitis C. The iminosugars cause misfolding of viral proteins, making the viruses non-infectious.

Cardiovascular
Cancer
Pulmonary
Infectious Disease